Arsenic Trioxide: Injectable solution for intravenous administration
-
The FDA approved the drug Arsenic Trioxide in 2000 for treating acute promyelocytic leukaemia (APL) who are refractory to or have relapsed from retinoid and anthracycline chemotherapy and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. Arsenic Trioxide is supplied as a sterile, nonpyrogenic, clear solution. The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukaemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukaemia (PML) retinoic acid receptor (RAR)-alpha. This drug is present in 10 mg single-dose vials for intravenous infusion. The active ingredient in the vials is Arsenic Trioxide with inactive ingredients sodium hydroxide and hydrochloric acid.
Arsenic Trioxide price is reasonable, and one can find this medication with several generic medicine suppliers. For further information on Arsenic Trioxide, dial 18008891064